Skip to Content
Morningstar

IQVIA Holdings Inc IQV

Morningstar Rating
Unlock
Stock XNYS Rating as of
$239.67 +7.38 (3.18%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

IQVIA Earnings: Healthy Results Drive Long-Term Growth; Raising Fair Value Estimate to $268

Rachel Elfman

IQVIA delivered solid second-quarter results, highlighted by stronger-than-expected performance from the technology and analytics, or TAS, segment, which rose 2.7% from the prior year and brought in nearly $1.5 billion in revenue. Macroeconomic challenges have led IQVIA's customers to spend more cautiously in the last few quarters, which had negatively affected sales in TAS by only growing 0.6% in the first quarter of 2024. Total second-quarter revenue of $3.8 billion represented 2.3% growth versus the prior year.

Read Full Report

Price vs Fair Value

View History
IQV is trading at a 440% premium.
Price
$239.67
Fair Value
$778.00
Uncertainty
Medium
1-Star Price
$678.30
5-Star Price
$352.80
Economic Moat
Djhvx
Capital Allocation
Smdxnbdf

Bulls Say, Bears Say

Bulls

IQVIA’s leading position in outsourced clinical trials allows it to create sticky client relationships, further honing clinical and regulatory expertise.

Bears

The company's next-generation solutions could lose traction among clients or fail to gain traction with regulatory bodies.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IQV is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$232.29
Day Range
$233.99–239.95
52-Week Range
$167.42–261.73
Bid/Ask
$225.98 / $251.82
Market Cap
$43.69 Bil
Volume/Avg
1.2 Mil / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
22.81
Price/Sales
2.92
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
0.85%

Company Profile

IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Core
Total Number of Employees
88,000
Website
https://www.iqvia.com

Competitors

Valuation

View More
Metric
IQV
MEDP
FTRE
Price/Earnings (Normalized)
 22.8135.8928.80
Price/Book Value
 6.5115.491.51
Price/Sales
 2.926.000.80
Price/Cash Flow
 17.7931.6680.67
Price/Earnings
IQV
MEDP
FTRE

Financial Strength

Metric
IQV
MEDP
FTRE
Quick Ratio
 0.750.821.26
Current Ratio
 0.850.881.47
Interest Coverage
 3.10—0.08
Quick Ratio
IQV
MEDP
FTRE

Profitability

Metric
IQV
MEDP
FTRE
Return on Assets (Normalized)
 7.37%21.49%−0.91%
Return on Equity (Normalized)
 31.57%62.19%−2.29%
Return on Invested Capital (Normalized)
 12.80%47.95%1.26%
Return on Assets
IQV
MEDP
FTRE
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Diagnostics & Research Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
VxffwnbklpLphqn$231.8 Bil
 Danaher Corp
DHR
HgpbrxvmHhvgp$197.8 Bil
 Agilent Technologies Inc
A
ZcgvnpbwrZmxt$40.1 Bil
 IDEXX Laboratories Inc
IDXX
KtgqnhkbgFdmhn$38.8 Bil
 Mettler-Toledo International Inc
MTD
BdzxrhjpnvFqflm$31.0 Bil
 Icon PLC
ICLR
PjqdxvmynXcrbbbg$26.8 Bil
 Illumina Inc
ILMN
BmkhrhkWckqfhs$19.2 Bil
 Waters Corp
WAT
ZybcnxdwcXdn$18.9 Bil
 Labcorp Holdings Inc
LH
LtfhthzzRydzgc$17.8 Bil

Sponsor Center